Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cobra Biologics and Novolytics Develop Bacteriophages Against Infection

Published: Wednesday, June 12, 2013
Last Updated: Wednesday, June 12, 2013
Bookmark and Share
Companies have achieved a breakthrough in the development of two Staphylococcus aureus-based phage products for Phase I clinical trials.

An existing process was transferred to Cobra’s phage team and a scope of work undertaken to further develop the process to increase yields for the two Staphylococcus aureus-based phage products. The controlled, high yield process provides Novolytics with a clear path forward to producing suitable GMP material for human clinical trials.

The worldwide emergence of ‘superbugs’ such as MRSA has coincided with the virtual drying up of new antibiotic drug development. Novolytics aims to lead the way in utilising nature’s own natural antidote, bacteriophages. The company’s lead product, NOVO12, is a phage cocktail administered as a gel for topical treatment of MRSA infections.

Cobra is set to present its methodology, approach, and acquired expertise in phage manufacture at the Phages 2013 conference taking place in Oxford, UK, in September 2013.

‘It is very exciting to be engaged with such novel phage products and to be actively assisting pioneering companies like Novolytics to introduce ground-breaking anti-infectives,’ said Peter Coleman, CEO of Cobra Biologics. ‘The phage team has considerable experience in developing processes for such novel products and looks forward to working closely with Novolytics.’

Novolytics CEO John Hardcastle added: ‘Cobra is helping Novolytics to produce bacteriophage cocktails that remain therapeutically active when produced to GMP standard and on an industrial scale. This is a critical factor for successful exploitation of the exciting potential that phage therapy offers.’


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cobra Biologics Appointed by University of Sheffield
Manufacturing service will scale production of growth hormone developed using ‘ProFuse’ Technology.
Tuesday, November 24, 2015
Cobra Biologics and The University of Manchester Announce Collaboration
Agreement brings together academic and industrial expertise for the scaled manufacture of therapeutic proteins.
Friday, September 25, 2015
Cobra Biologics Develop Special Cell Line for Alligator Bioscience
The cell line designed expresses monoclonal antibodies that have been vital for the success of a clinical trial ran by Alligator Biosciences.
Thursday, May 28, 2015
Cobra Biologics Appoints CSO
Company announces the appointment of Dr Daniel C. Smith as its Chief Scientific Officer.
Wednesday, May 07, 2014
Cobra Biologics Granted Approval for Research Tax Credit
Company has recognized as an approved service provider for the period 2013 to 2015.
Wednesday, April 02, 2014
Cobra Biologics and BioCancell Announce Agreement
Agreement to manufacture promising cancer therapy drug.
Tuesday, March 04, 2014
GMP Certification Boost for Cobra Biologics
Extended certification to include QC testing of registered products.
Wednesday, February 12, 2014
Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody
New contract manufacturing partnership for Algeta’s fourth Targeted Thorium Conjugate program.
Tuesday, January 15, 2013
Cobra Biologics’ Growth is Strengthened
A new non-executive director joins Cobra’s board to support expansion plans.
Tuesday, October 23, 2012
Cobra Biologics and Alligator Bioscience AB Sign Monoclonal Antibody Manufacturing Agreement
Agreement for the production of monoclonal antibody drug substance and drug product for pre-clinical studies and Phase I-II clinical trials.
Tuesday, June 19, 2012
Cobra Biologics’ Expansion Continues
Appointment of three non-executive directors and two business development managers to Cobra Biologics’ board.
Tuesday, February 14, 2012
Cobra Biologics Acquires Unitech Pharma Group
Acquisition to expand Cobra’s capacity and biopharmaceutical service offering.
Tuesday, November 01, 2011
Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!